The latest price target for Foghorn Therapeutics (NASDAQ:FHTX) was reported by Wedbush on March 12, 2026. The analyst firm set a price target for $10.00 expecting FHTX to rise to within 12 months (a possible 102.84% upside). 10 analyst firms have reported ratings in the last year.

The latest analyst rating for Foghorn Therapeutics (NASDAQ:FHTX) was provided by Wedbush, and Foghorn Therapeutics reiterated their outperform rating.

There is no last upgrade for Foghorn Therapeutics

There is no last downgrade for Foghorn Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Foghorn Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Foghorn Therapeutics was filed on March 12, 2026 so you should expect the next rating to be made available sometime around March 12, 2027.

While ratings are subjective and will change, the latest Foghorn Therapeutics (FHTX) rating was a reiterated with a price target of $10.00 to $10.00. The current price Foghorn Therapeutics (FHTX) is trading at is $4.93, which is out of the analyst’s predicted range.